VERT-LE-PETIT, FRANCE (March 12, 2018) — Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services from the polypeptide design up to delivery of small quantity of polymer and PMC Isochem will use GMP production facility for clinical batch and commercial supply. In addition, PMC Isochem develops and
MEMPHIS, TN (December 5, 2017) — PMC Biogenix Inc. announces that effective January 1, 2018 or as contracts permit, prices for products sold under the trademarks Armoslip®, Hystrene®, Industrene®, Kemamide®, Kemester®, and Lubrazinc® will increase by 3% (three percent). Customers with questions should contact their sales manager or their local customer service contact.   About
MOUNT LAUREL, NJ (December 4, 2017) — PMC Group France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of the pharma business of Isochem SAS of France. This is a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale
MOUNT LAUREL, NJ (October 28, 2017) — PMC YM-Pharma Private Ltd., a subsidiary of PMC Group International, an independent arm of PMC Group Inc., announced the acquisition of the assets of Yegna Manojavam Drugs and Chemicals Ltd (YMDCL) of Hyderabad, India. The cGMP manufacturing facility of YMDCL is one of the largest fluoroquinolone drug manufacturers